Novartis Animal Health Inc. has completed an agreement with Luitpold Pharmaceuticals, Inc. that grants marketing rights for Adequan® Equine to Novartis in all major equine markets outside the U.S. The first launch of Adequan® Equine by Novartis will take place in Canada in June.

Adequan® Equine is indicated for treating joint dysfunction and lameness in horses caused by injury or degenerative problems. It is available for intramuscular and intra-articular administration. Adequan® is also indicated for treating joint dysfunction and lameness caused by injury or degenerative problems in dogs.

Mickey McDermott from Novartis' Communications Dept told VetSurgeon that the timing of Adequan's arrival in the UK depends on how long it takes to complete the registration transfers, but that the company hopes it'll be before the end of the year.

PS: Whilst you're here, take a moment to see our latest job opportunities for vets.